Premium
Effects of cidofovir on a novel cell‐based test system for recurrent respiratory papillomatosis
Author(s) -
Donne Adam J.,
Hampson Lynne,
He Xiao T.,
Rothera Michael P.,
Homer Jarrod J.,
Hampson Ian N.
Publication year - 2007
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.20572
Subject(s) - cidofovir , recurrent respiratory papillomatosis , flow cytometry , cell culture , cell , cancer research , papilloma , microbiology and biotechnology , virology , biology , chemistry , medicine , virus , pathology , genetics
Abstract Background. Cidofovir has been reported to have activity against human papillomavirus (HPV) type 16, but no laboratory studies have been performed on HPV type 6, the main cause of recurrent respiratory papillomatosis (RRP). Methods. HPV6b E6 cDNA‐based C33A (non‐HPV cervical carcinoma) cell line was produced. Two different doses of cidofovir were applied to parent C33A, C33AT6E6, and C33AT16E6 (HPV 16). Growth and flow cytometry analysis were performed. Results. Polymerase chain reaction confirmed HPV6 E6 expression in C33AT6E6 cells. High‐dose cidofovir was found to be toxic to all cell lines. Low‐dose exposure was found to be toxic to C33AT16E6 cells at 3 days, whereas C33A and C33AT6E6 showed minimal toxicity at 6 days and earlier recovery following drug withdrawal. Conclusions. Cidofovir showed nonspecific toxicity against all 3 cell lines tested. HPV16 E6 expressing cells were more sensitive than parent or HPV6 E6 expressing cells. Cidofovir has no selective advantage for the RRP‐related HPV6 E6 expressing cell line. © 2007 Wiley Periodicals, Inc. Head Neck, 2007